Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

NCT ID: NCT07158489

Last Updated: 2025-09-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 47 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-01
• Study Completion Date: 2029-03-31

Brief Summary

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

Detailed Description

Lung cancer is the most frequently diagnosed cancer worldwide, with approximately 2.5 million new cases and 1.8 million deaths annually. Most cases are diagnosed at an advanced stage, necessitating systemic therapy. Although chemoimmunotherapy (CIT) has improved outcomes, disease progression remains inevitable, and second-line treatments offer limited efficacy. Gemcitabine, a cytidine analogue, interferes with DNA synthesis and exhibits immunomodulatory effects, including increased effector T-cell infiltration and reduced regulatory T-cell activity. Preclinical studies have shown that gemcitabine enhances antitumor immune responses when combined with immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies.

Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways. It binds to PD-1 on activated T cells and VEGF involved in tumor angiogenesis. The combination of gemcitabine and ivonescimab is hypothesized to synergistically improve antitumor activity in patients with advanced NSCLC who have progressed after CIT.

Preclinical evidence from mouse models of mesothelioma demonstrated that combining gemcitabine with immunotherapy significantly increased survival and lymphocyte infiltration at the tumor site. This effect was negated by dexamethasone, highlighting the importance of immune modulation. Clinical observations in mesothelioma patients further support the potential of this combination.

Gemcitabine is a standard of care (SoC) for several solid tumors, including NSCLC. Its immunostimulatory properties make it a suitable candidate for combination with ICIs. Ivonescimab has shown superior efficacy compared to pembrolizumab in PD-L1+ NSCLC patients in first-line settings. Despite ongoing trials exploring similar combinations, none have investigated gemcitabine with ivonescimab.

This Phase II trial aims to assess the antitumor activity of gemcitabine combined with ivonescimab in patients with advanced NSCLC who have limited therapeutic options. Gemcitabine will be administered according to standard treatment recommendations, while ivonescimab will be given at 20 mg/kg every three weeks (q3w), consistent with previous trials.

The primary objective is to evaluate the objective response rate (ORR) based on RECIST v1.1 criteria, with independent response review. The study is inclusive across sex, gender, and ethnicity, and all materials will use gender-inclusive language. A positive outcome may support the adoption of this combination as a new standard treatment for relapsed NSCLC.

Conditions

NSCLC; NSCLC (Advanced Non-small Cell Lung Cancer)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gemcitabine + Ivonescimab in Advanced NSCLC Resistant to Immunotherapy

Group Type: EXPERIMENTAL

Gemcitabine + Ivonescimab

Intervention Type: DRUG

The trial combines two Investigational Medicinal Products (IMPs):

• Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC).
• Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation.

Interventions

Gemcitabine + Ivonescimab

The trial combines two Investigational Medicinal Products (IMPs):

• Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC).
• Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures including patient screening.
• Confirmed squamous or non-squamous mNSCLC stage IIIB-IV (based on 9th edition Tumor-Node-Metastasis (TNM) classification of lung cancers with disease recurrence or progression during or after one or more prior immunotherapy or CIT regimens for metastatic disease.
• Patients with treated and stable central nervous system (CNS) metastases are eligible, if:

• Previous CNS-directed therapy has been completed at least 4 weeks prior to treatment start.
• No evidence of progression after completion of CNS-directed therapy as ascertained by clinical examination and brain imaging with Magnetic Resonance Imaging (MRI) or CT.25
• Patients with known HIV-infection are eligible, if:

• CD4+ T-cell counts are ≥ 350 cells/µl
• No history of AIDS-defining opportunistic infection within past 12 months
• Patient agrees to concomitant antiretroviral therapy (ART) if not currently on ART, or is on ART for ˃ 4 weeks and has a HIV viral load ˂ 400 copies/ml.26
• Patients with a previously treated malignancy are eligible if this is clinically stable and does not require concurrent tumor-directed treatment.

Exception: patients suffering from prostate cancer under hormonal ablation therapy (hormone sensitive disease).

• Patients with measurable disease according to RECIST v1.1.
• Availability of newly collected or archival (maximum 3 months) samples for TR prior to treatment initiation.
• Age ≥ 18 years
• ECOG performance status 0-2.
• Adequate bone marrow function: absolute neutrophil count ≥ 1.5 x 109/l, platelet count ≥ 100 x 109/l, hemoglobin ≥ 90 g/l.

6.1.11 Adequate hepatic function: total bilirubin ≤ 1.5 x upper limit of normal ([ULN]; except for patients with Gilbert's disease ≤ 3.0 x ULN), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN for patients with hepatic metastasis.

• Adequate renal function: estimated glomerular filtration rate (eGFR) ≥ 40 ml/min/1.73 m2 (according to the Chronic Kidney Disease Epidemiology Collaboration) abbreviated formula CKD-EPI formula.
• Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must use highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and until 6 months after the last dose of investigational drug . A negative serum or urine pregnancy test before starting trial treatment is required for all women of childbearing potential.
• Men agree not to donate sperm or father a child during trial treatment and until 6 months after the last administration of investigational drug.
• Patients give their consent to participate in TR projects and providing the mandatory samples.

Exclusion Criteria

• Symptomatic brain metastases.
• Prior treatment with gemcitabine in combination with immunotherapies.
• Tumor progression within the first 8 weeks from start of first-line treatment.
• Activating EGFR or ALK mutations.
• Concomitant use of other anti-cancer drugs or radiotherapy.
• Major surgery within 1 month prior to treatment start.
• Known history of any uncontrolled active systemic infection requiring intravenous antimicrobial treatment.
• Known history of tuberculosis, primary immunodeficiency, allogeneic tissue/solid organ transplant, or receipt of live attenuated vaccine.
• History of interstitial lung disease or severe pneumonitis.
• Concomitant use of corticosteroids as premedication for gemcitabine therapy.
• Concomitant or prior use of immunosuppressive medication such as interferon or methotrexate within 28 days prior to trial treatment start, with the exceptions of local (i.e., intranasal, inhaled and topical) corticosteroids.
• Major blood vessel tumor invasion.
• Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to study treatment initiation.
• Unstable angina, myocardial infarction, congestive heart failure (NYHA classification Grade ≥2;27) or vascular disease (e.g., aortic aneurysm at risk of rupture) that required hospitalization within 12 months prior to study treatment initiation, or other cardiac impairment that may affect the safety evaluation of the study drug (e.g., poorly controlled arrhythmias, myocardial ischemia).
• History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months prior to study treatment initiation.
• History of arterial thromboembolic event, venous thromboembolic event of Grade ≥3 as specified in NCI CTCAE v5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to study treatment initiation.
• Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks prior to study treatment initiation.
• History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to study treatment initiation.
• Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information or to the Investigator's Brochure (IB).
• Known or suspected hypersensitivity to gemcitabine or ivonescimab or to any component of the trial drugs.
• History of bleeding tendencies or coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks prior to registration, including but not limited to:

• Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots).

Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.

• Nasal bleeding /epistaxis (bloody nasal discharge is allowed).
• Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to registration is not allowed. The use of full-dose anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time is within therapeutic limits according to the medical standard of the enrolling institution.

• Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic pressure ≥ 100 mmHg after oral antihypertensive therapy.
• Active autoimmune or lung disease requiring systemic therapy (e.g., with disease modifying drugs, prednisone >10 mg daily or equivalent, immunosuppressant therapy) within 2 years prior to registration, however the following will be allowed:
• Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.
• Intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections is permitted.

• Has pre-existing peripheral neuropathy that is ≥ Grade 2 by NCI CTCAE v5.0.
• Uncontrolled pleural effusions, pericardial effusions, or ascites that is clinically symptomatic.

Note: Patients managed with indwelling catheters (e.g., PleurX) are allowed.

• History of non-infectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease.
• Active or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Swiss Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alessandra Curioni-Fontecedro, Prof

Role: STUDY_CHAIR

Cantonal Hospital Fribourg / University of Fribourg

Locations

Kantonsspital Baden

Baden, , Switzerland

Universitätsspital Basel

Basel, , Switzerland

IOSI Ospedale Regionale di Bellinzona e Valli

Bellinzona, , Switzerland

Kantonsspital Graubuenden

Chur, , Switzerland

Hôpital Fribourgeois - Hôpital Cantonal

Fribourg, , Switzerland

Hôpitaux Universitaires de Genève

Geneva, , Switzerland

Kantonsspital Winterthur

Winterthur, , Switzerland

Countries

Switzerland

Central Contacts

Jana Musilova, PhD

Role: CONTACT

trials@swisscancerinstitute.ch

031 389 91 91 ext. +41

Other Identifiers

SAKK 18/25

Identifier Type: -

Identifier Source: org_study_id